SlideShare ist ein Scribd-Unternehmen logo
1 von 18
European cancer
patient advocacy:
Introduction to the community,
key stakeholder interfaces
and key initiatives
ESO Masterclass, Lisbon/PT, 23 Feb 2018
Jan Geissler
jan@patvocates.net
European cancer patient community:
What I will cover in this session
 Overview on Networks and umbrellas of the patient community
 Collaboration with professional societies and multi-stakeholder initiatives
 Involvement of the patient community in…
• European Reference Networks
• public private partnerships and industry initiatives
• regulatory authorities
• medicines research & development
• CABs, evidence-based advocacy, capacity building, EHA
Please make sure you ask your questions!
Patient advocacy operates on three levels
Business Use Only 3
Patient support
Inform, support, navigate
Health policy
Influence health policy, patient care
Research
Contribute in partnership with
clinicians, networks and industry
EUROPEAN
CANCER
PATIENT
COALITION:
>400 mostly national
patient organisations
WECAN:
Workgroup of leaders
of 20 European
Cancer patient
Advocacy
Networks
ALL CANCERS
RARE
CANCERS
HEMA-
TOLOGY
PAEDI-
ATRIC
EURORDIS:
>600 patient
organisations
in rare diseases
EUROPEAN PATIENTS FORUM
European Cancer Patient Networks
 Informal workgroup and “think tank” of leaders of 20 pan-European cancer
patient umbrella organisations, initiated in 2015
 Share workload for meetings, coordinate our representation in committees
 Form a "think tank" to develop ideas on how to cross bridges between
advocacy
 Share resources and concepts on joint patient-driven evidence
 First activities:
• Reasonable Agreements on interaction of patients advocates with industry
• Fair Market Value project
• Coordinated approach to education of advocates
• Positioning towards Stakeholder Engagement
• Coordination of contribution to research in cancer advocacy
COMMON CANCERS:
• European Men Health Forum
(EMHF)
• European Network of
Gynaecological Cancer
Advocacy Groups (ENGAGe)
• EuropaColon
• Europa Donna
• Europa Uomo
• Lung Cancer Europe (LuCE)
• Melanoma Patients Network
Europe (MPNE)
• Pancreatic Cancer Europe
Network
RARE CANCERS:
• European Organisation of Rare
Diseases (EURORDIS)
• International Brain Tumour Alliance
(IBTA)
• International Kidney Cancer
Coalition (IKCC)
• International Neuroendocrine
Cancer Alliance (INCA)
• Thyroid Cancer Alliance (TCA)
• Sarcoma Patient
Advocates European
Network (SPAEN)
• Chordoma Foundation
• European Morbus
Waldenström Network
• Lymphoma Coalition Europe
• Acute Leukemia Advocates
Network
• MDS Alliance
• CML Advocates Network
• CLL Advocates Network
• MPN Advocates Network
• Myeloma Patients Europe (MPE)
• Childhood Cancer International
(CCI)
ALL CANCERS
RARE
CANCERS
HEMA-
TOLOGY
PAEDI-
ATRIC
European disease-specific patient advocacy networks
Four European Reference Networks (ERNs) in cancer launched in
2017: Hematology, Rare Cancers, Pediatrics, Genetic cancers
• Initiative of EU and Member States
• Networks of Centers of Excellence
and local healthcare providers
• Establish national healthcare
pathways across all EU countries
• Development and adherence to
clinical guidelines
• Integration of healthcare and
research infrastructure
In 2016, European Patient Advocacy
Groups’ Representatives (ePAGs) were
elected by the patient community to
represent patients in the ERNs
ALL CANCERS
RARE
CANCERS
HEMA-
TOLOGY
PAEDI-
ATRIC
Patient Organisations
Workgroup
& European Affairs
Committee
Patient Advocacy
Committee with
16 PO umbrellas
& full board seat
Patient Organisations
Workgroup
& Full Membership
for patient advocates
Institutional
Advisory Board,
Training Courses
Patient
Roundtable
Collaboration with professional
societies and multi-stakeholder
initiatives
Patient involvement in regulatory authorities (e.g. EMA)
11 pan-European hematology networks with 264 European member
organisations in Europe (in EuroBloodNet ERN)
ALL
CANCERS
RARE
CANCERS
HEMA-
TOLOGY
PAEDI-
ATRIC
Chronic Myeloid Leukemia
Chronic Lymhocytic Leukemia
Hemochromatosis
Hemophilia
Immune Thrombocytopenia
Lymphoma
Myelodysplastic Syndromes
Myeloma
Myeloproliferative Neoplasms
Thalassemia
Waldenström's
Macroglobulinemia
ePAG representation
Amanda Bok (EHC)
Ananda Plate (MPE)
Angelo Loris Brunetta (TIF)
Jan Geissler (LePAF)
Pierre Aumont (EWMNetwork)
Sophie Wintrich (MDS Alliance)
Maria Piggin (PNH)
??? (Iron disorders)
European Reference Network (ERN) in Rare Cancers:
EURACAN
ALL
CANCERS
RARE
CANCERS
HEMA-
TOLOGY
PAEDI-
ATRIC
Clinical domains
Sarcoma
Female genital
Male genital
Neuroendocrine
Digestive tract
Endocrine
Head and Neck
Skin/Eye
Brain/spinal cord
ePAG involved in
Steering Group,
Task Forces and
Clinical Domains
Kathy Oliver (IBTA)
Isabelle Manneh-Vangramberen (ECPC)
Estelle Lecointe (SPAEN)
Markus Wartenberg (SPAEN)
Teodora Kolarova (INCA)
Jo Grey (AMEND UK)
Iain Galloway (MPNE)
Patient involvement in practice within the R&D life cycle
Source: Geissler, Ryll, Uhlenhopp, Leto (2016)
Therapeutic Innovation & Regulatory Science (2017), doi: 10.1177/2168479017706405
High
expertise
in disease
area
required
Medium
expertise
in disease
area
required
Research design and
planning
Research priorities Research conduct and operations
Dissemination
communication
post-approval
Protocol
synopsis
Fundraising for
research
Practical
considerations
Patient
information
Informed
consent
Ethics
review
Study
reporting
Health Technology
Assessment
Post-study
communication
Trial
Steering
Committee
Information to
participant
Setting
research
priorities
Protocol
design
Investigator
meetings
Data &
Safety
Monitoring
Committee
Regulatory
Affairs
Involvement in public private partnerships and industry
initiatives
 Innovative Medicines Initiative
• EUPATI (Coordination)
• Big Data: HARMONY, (BIG4)
• GetReal
• PARADIGM
• IMI Strategic Governance Group Oncology
 EFPIA Patient Think Tank
 Patient involvement in Investigator Meetings,
Trial Protocol Review, Data Safety Monitoring Boards
Community Advisory Boards, e.g. CML, (Hematology)
Two-way dialogue of the world-wide leaders of
the CML community with clinical development,
medical affairs, market access, patient relations to
improve patients’ well-being and outcomes
 Drug development pipeline of the companies
 Improving access to drugs
 Improve collaboration of companies with
community
 Discuss patient information developed by
companies
CAB
Spectrum of further
activities
 Evidence-based advocacy
• CML Adherence Survey,
CML Therapy-Free Remission
project
• MPE Atlas of Access to Myeloma
Treatment
• Lymphoma Coalition Access
Report
• More of this at this ESO
Masterclass!
 Capacity building
• This ESO Masterclass in cancer
patient advocacy
• SPAEN‘s SmartStart
• EUPATI
Perceived barriers to access across countries in relation to self declared needs & health expenditure
(Source: MPE Atlas of Access of to Myeloma Treatment, 2016)
Expert patients for patient involvement in R&D:
European Patients‘ Academy
 14-month expert training course for
patient advocates on medicines R&D ,
98 graduates from 58 disease areas
 500.000 individual users of EUPATI
Toolbox on eupati.eu
1. Discovery of
Medicines
2. Pre-clinical
Development
3. Clinical
Development
4. Clinical Trials
5. Regulatory Affairs,
Drug Safety,
Pharmacovigilance
6. Health Technology
Assessment
EUPATI Patient Expert Training Courses 1+2:
98 graduates from 58 disease areas
1 Achondroplasia
1 Adrenoleukodystrophy
1 Allergy and airways diseases
1 Arthritis
1
Asperger´s syndrome/Fibromyalge and
Chronic Fatigue Syndrome
1 Asthma
1 Attention Deficit Hyperactivity Disorder
1 Autoimmune disease
1 Brain tumours
3 Breast cancer
4 Cancer
1 Cardiovascular
1 Chronic Fatigue
1 Coeliacy
1 Cystic Fibrosis
3 Diabetes
1 Disability
1 Ehlers-Danlos Syndrome
1 Endocrine tumours
2 Endometriosis
1 Epidermolysis bullosa (EB)
1 Fibromyalgia
2 Gaucher Disease
4 General advocacy
1 Genetic Disorders
3 Haemophilia
10 Hematological Cancer
1 Hereditary haemorrhagic telangiectasia (HHT)
2 HIV
1 Incontinent patients
1 Leber’s Hereditary Optic Neuropathy
1 Lipoprotein Lipase Deficiency
1 Lung conditions
1 Lupus
1 McCune Albright syndrome
3 Melanoma
1 Mental Health
4 Multiple Sclerosis
2 Muscular atrophy
6 Muscular Dystrophy
1 Neurofybromatosis
2 Paediatric
1 Paediatric Cancer
1 Parkinson's Disease
1 Primary Immunodeficiences
1
Primary Sclerosing Cholangitis/liver and bile duct
disease
1 Pulmonary Hypertension
4 Rare Diseases
1 Rare diseases/Friedrich’s Ataxia
1 Rare diseases/Paroxysmal nocturnal hemoglobinuria
1 Rare diseases/Pituitary
1 Rare diseases/Tuberous Sclerosis
1 Respiratory diseases
1 Rett Syndrome
6 Rheumatic diseases
1 Sight loss
1 Thalassaemia
1 Vasculitis
Names on www.eupati.eu:
Questions?
Jan Geissler
jan@patvocates.net
ALL CANCERS
RARE
CANCERS
HEMA-
TOLOGY
PAEDI-
ATRIC

Weitere ähnliche Inhalte

Ähnlich wie European Cancer Patient Advocacy: Introduction to the community, key stakeholder interfaces and key initiatives (Jan Geissler)

The patient voice: turning health policy into opportunity - Jan Geissler - ES...
The patient voice: turning health policy into opportunity - Jan Geissler - ES...The patient voice: turning health policy into opportunity - Jan Geissler - ES...
The patient voice: turning health policy into opportunity - Jan Geissler - ES...patvocates
 
Access to treatment, care and clinical trials by patients with rare cancers...
Access to treatment, care and clinical trials by patients with rare cancers...Access to treatment, care and clinical trials by patients with rare cancers...
Access to treatment, care and clinical trials by patients with rare cancers...patvocates
 
EuroBioForum 2013 - Day 1 | Emmanuelle Benzimra
EuroBioForum 2013 - Day 1 | Emmanuelle BenzimraEuroBioForum 2013 - Day 1 | Emmanuelle Benzimra
EuroBioForum 2013 - Day 1 | Emmanuelle BenzimraEuroBioForum
 
EANM patient information on thyroid cancer
EANM patient information on thyroid cancerEANM patient information on thyroid cancer
EANM patient information on thyroid cancerMarika Porrey
 
Mark Lawler - European Cancer Concord and Queens University Belfast - 8th Eur...
Mark Lawler - European Cancer Concord and Queens University Belfast - 8th Eur...Mark Lawler - European Cancer Concord and Queens University Belfast - 8th Eur...
Mark Lawler - European Cancer Concord and Queens University Belfast - 8th Eur...Cittadinanzattiva onlus
 
"Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To...
"Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To..."Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To...
"Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To...Vall d'Hebron Institute of Research (VHIR)
 
2009 Convegno Malattie Rare Lipucci Di Paola [22 01]
2009 Convegno Malattie Rare Lipucci Di Paola [22 01]2009 Convegno Malattie Rare Lipucci Di Paola [22 01]
2009 Convegno Malattie Rare Lipucci Di Paola [22 01]cmid
 
Launch auf the European Cancer Patients Bill of Rights: Addressing the unequ...
Launch auf the European Cancer Patients Bill of Rights: Addressing the unequ...Launch auf the European Cancer Patients Bill of Rights: Addressing the unequ...
Launch auf the European Cancer Patients Bill of Rights: Addressing the unequ...jangeissler
 
Survivorship parliamentary-report
Survivorship parliamentary-reportSurvivorship parliamentary-report
Survivorship parliamentary-reportAlina Comanescu
 
Alcohol intake and breast cancer in the European prospective investigation in...
Alcohol intake and breast cancer in the European prospective investigation in...Alcohol intake and breast cancer in the European prospective investigation in...
Alcohol intake and breast cancer in the European prospective investigation in...BARRY STANLEY 2 fasd
 
EUPATI Status Update at EMA PCWP Meeting, 26 Nov 2015
EUPATI Status Update at EMA PCWP Meeting, 26 Nov 2015EUPATI Status Update at EMA PCWP Meeting, 26 Nov 2015
EUPATI Status Update at EMA PCWP Meeting, 26 Nov 2015jangeissler
 
10-3. Rare disease registries. Samantha Parker (eng)
10-3. Rare disease registries. Samantha Parker (eng)10-3. Rare disease registries. Samantha Parker (eng)
10-3. Rare disease registries. Samantha Parker (eng)KidneyOrgRu
 
The emergence of the e-patient
The emergence of the e-patientThe emergence of the e-patient
The emergence of the e-patientjangeissler
 
Patient Advocates in Cancer Research: European Patients’ Perspective - Jan ...
Patient Advocates in Cancer Research: European Patients’ Perspective - Jan ...Patient Advocates in Cancer Research: European Patients’ Perspective - Jan ...
Patient Advocates in Cancer Research: European Patients’ Perspective - Jan ...patvocates
 
tomislav vurusic - hiv treatment and activism
 tomislav vurusic -  hiv treatment and activism tomislav vurusic -  hiv treatment and activism
tomislav vurusic - hiv treatment and activismPartnerships in Health
 
EPAD 2017 - Jan Willem Van de Loo
EPAD 2017 - Jan Willem Van de LooEPAD 2017 - Jan Willem Van de Loo
EPAD 2017 - Jan Willem Van de LooMarc van Gurp
 

Ähnlich wie European Cancer Patient Advocacy: Introduction to the community, key stakeholder interfaces and key initiatives (Jan Geissler) (20)

The patient voice: turning health policy into opportunity - Jan Geissler - ES...
The patient voice: turning health policy into opportunity - Jan Geissler - ES...The patient voice: turning health policy into opportunity - Jan Geissler - ES...
The patient voice: turning health policy into opportunity - Jan Geissler - ES...
 
Access to treatment, care and clinical trials by patients with rare cancers...
Access to treatment, care and clinical trials by patients with rare cancers...Access to treatment, care and clinical trials by patients with rare cancers...
Access to treatment, care and clinical trials by patients with rare cancers...
 
EuroBioForum 2013 - Day 1 | Emmanuelle Benzimra
EuroBioForum 2013 - Day 1 | Emmanuelle BenzimraEuroBioForum 2013 - Day 1 | Emmanuelle Benzimra
EuroBioForum 2013 - Day 1 | Emmanuelle Benzimra
 
EANM patient information on thyroid cancer
EANM patient information on thyroid cancerEANM patient information on thyroid cancer
EANM patient information on thyroid cancer
 
Mark Lawler - European Cancer Concord and Queens University Belfast - 8th Eur...
Mark Lawler - European Cancer Concord and Queens University Belfast - 8th Eur...Mark Lawler - European Cancer Concord and Queens University Belfast - 8th Eur...
Mark Lawler - European Cancer Concord and Queens University Belfast - 8th Eur...
 
Julio E. Celis-Investigar, educar, dialogar
Julio E. Celis-Investigar, educar, dialogarJulio E. Celis-Investigar, educar, dialogar
Julio E. Celis-Investigar, educar, dialogar
 
"Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To...
"Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To..."Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To...
"Enfermedades Minoritarias y Medicamentos huérfanos en la UE" by Dr. Josep To...
 
2009 Convegno Malattie Rare Lipucci Di Paola [22 01]
2009 Convegno Malattie Rare Lipucci Di Paola [22 01]2009 Convegno Malattie Rare Lipucci Di Paola [22 01]
2009 Convegno Malattie Rare Lipucci Di Paola [22 01]
 
Launch auf the European Cancer Patients Bill of Rights: Addressing the unequ...
Launch auf the European Cancer Patients Bill of Rights: Addressing the unequ...Launch auf the European Cancer Patients Bill of Rights: Addressing the unequ...
Launch auf the European Cancer Patients Bill of Rights: Addressing the unequ...
 
Survivorship parliamentary-report
Survivorship parliamentary-reportSurvivorship parliamentary-report
Survivorship parliamentary-report
 
Alcohol intake and breast cancer in the European prospective investigation in...
Alcohol intake and breast cancer in the European prospective investigation in...Alcohol intake and breast cancer in the European prospective investigation in...
Alcohol intake and breast cancer in the European prospective investigation in...
 
EUPATI Status Update at EMA PCWP Meeting, 26 Nov 2015
EUPATI Status Update at EMA PCWP Meeting, 26 Nov 2015EUPATI Status Update at EMA PCWP Meeting, 26 Nov 2015
EUPATI Status Update at EMA PCWP Meeting, 26 Nov 2015
 
10-3. Rare disease registries. Samantha Parker (eng)
10-3. Rare disease registries. Samantha Parker (eng)10-3. Rare disease registries. Samantha Parker (eng)
10-3. Rare disease registries. Samantha Parker (eng)
 
ODRD 2016
ODRD 2016ODRD 2016
ODRD 2016
 
The emergence of the e-patient
The emergence of the e-patientThe emergence of the e-patient
The emergence of the e-patient
 
Patient Advocates in Cancer Research: European Patients’ Perspective - Jan ...
Patient Advocates in Cancer Research: European Patients’ Perspective - Jan ...Patient Advocates in Cancer Research: European Patients’ Perspective - Jan ...
Patient Advocates in Cancer Research: European Patients’ Perspective - Jan ...
 
tomislav vurusic - hiv treatment and activism
 tomislav vurusic -  hiv treatment and activism tomislav vurusic -  hiv treatment and activism
tomislav vurusic - hiv treatment and activism
 
Session 2 segolene_ayme
Session 2 segolene_aymeSession 2 segolene_ayme
Session 2 segolene_ayme
 
About ecancer
About ecancerAbout ecancer
About ecancer
 
EPAD 2017 - Jan Willem Van de Loo
EPAD 2017 - Jan Willem Van de LooEPAD 2017 - Jan Willem Van de Loo
EPAD 2017 - Jan Willem Van de Loo
 

Mehr von jangeissler

Relevanz von Laienzusammenfassungen von Studienergebnissen für Patienten
Relevanz von Laienzusammenfassungen von Studienergebnissen für Patienten Relevanz von Laienzusammenfassungen von Studienergebnissen für Patienten
Relevanz von Laienzusammenfassungen von Studienergebnissen für Patienten jangeissler
 
Don't just talk about patient centricity - put meaningful patient engagement ...
Don't just talk about patient centricity - put meaningful patient engagement ...Don't just talk about patient centricity - put meaningful patient engagement ...
Don't just talk about patient centricity - put meaningful patient engagement ...jangeissler
 
CML: A tiger in the cage? A (European) perspective on CML disease management
CML: A tiger in the cage? A (European) perspective on CML disease managementCML: A tiger in the cage? A (European) perspective on CML disease management
CML: A tiger in the cage? A (European) perspective on CML disease managementjangeissler
 
Sicht der Patienten auf Real World Data, Register und Versorgungsdaten
Sicht der Patienten auf Real World Data, Register und VersorgungsdatenSicht der Patienten auf Real World Data, Register und Versorgungsdaten
Sicht der Patienten auf Real World Data, Register und Versorgungsdatenjangeissler
 
Überblick der Aktivitäten von Leukämie-Online und CML Advocates Network
Überblick der Aktivitäten von Leukämie-Online und CML Advocates NetworkÜberblick der Aktivitäten von Leukämie-Online und CML Advocates Network
Überblick der Aktivitäten von Leukämie-Online und CML Advocates Networkjangeissler
 
Andreas Willer - Rehabilitation für Patienten mit CML
Andreas Willer - Rehabilitation für Patienten mit CMLAndreas Willer - Rehabilitation für Patienten mit CML
Andreas Willer - Rehabilitation für Patienten mit CMLjangeissler
 
Umfrage zur Therapiefreien Remission (TFR) der CML-Patientengemeinschaft
Umfrage zur Therapiefreien Remission (TFR) der CML-PatientengemeinschaftUmfrage zur Therapiefreien Remission (TFR) der CML-Patientengemeinschaft
Umfrage zur Therapiefreien Remission (TFR) der CML-Patientengemeinschaftjangeissler
 
Patientenperspektive im Studiendesign
Patientenperspektive im Studiendesign Patientenperspektive im Studiendesign
Patientenperspektive im Studiendesign jangeissler
 
Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldjangeissler
 
Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldjangeissler
 
Reasonable Legal Agreements between Patient Advocates and Pharma Companies
Reasonable Legal Agreements between Patient Advocates and Pharma CompaniesReasonable Legal Agreements between Patient Advocates and Pharma Companies
Reasonable Legal Agreements between Patient Advocates and Pharma Companiesjangeissler
 
Bericht LeukaNET / leukaemie-online.de und CML Advocates Network
Bericht LeukaNET / leukaemie-online.de und CML Advocates NetworkBericht LeukaNET / leukaemie-online.de und CML Advocates Network
Bericht LeukaNET / leukaemie-online.de und CML Advocates Networkjangeissler
 
How to get the most of the EHA congress as a CML patient advocate
How to get the most of the EHA congress as a CML patient advocateHow to get the most of the EHA congress as a CML patient advocate
How to get the most of the EHA congress as a CML patient advocatejangeissler
 
European Patient Perspective on Access and Innovation with Multiplex Genomic ...
European Patient Perspective on Access and Innovation with Multiplex Genomic ...European Patient Perspective on Access and Innovation with Multiplex Genomic ...
European Patient Perspective on Access and Innovation with Multiplex Genomic ...jangeissler
 
Häufige Fragen von CML-Patienten und Welt-CML-Tag 2017
Häufige Fragen von CML-Patienten und Welt-CML-Tag 2017Häufige Fragen von CML-Patienten und Welt-CML-Tag 2017
Häufige Fragen von CML-Patienten und Welt-CML-Tag 2017jangeissler
 
CML: What's New at EHA? Tim Brümmendorf, EHA Capacity Building Session, EHA c...
CML: What's New at EHA? Tim Brümmendorf, EHA Capacity Building Session, EHA c...CML: What's New at EHA? Tim Brümmendorf, EHA Capacity Building Session, EHA c...
CML: What's New at EHA? Tim Brümmendorf, EHA Capacity Building Session, EHA c...jangeissler
 
How to get the most of EHA as a patient advocate
How to get the most of EHA as a patient advocateHow to get the most of EHA as a patient advocate
How to get the most of EHA as a patient advocatejangeissler
 
PCR-Info-Projekt (Cornelia Borowczak)
PCR-Info-Projekt (Cornelia Borowczak)PCR-Info-Projekt (Cornelia Borowczak)
PCR-Info-Projekt (Cornelia Borowczak)jangeissler
 
The Networked Patient Group: How technology changes the face of patient advocacy
The Networked Patient Group: How technology changes the face of patient advocacyThe Networked Patient Group: How technology changes the face of patient advocacy
The Networked Patient Group: How technology changes the face of patient advocacyjangeissler
 
Tripartite dimension of interaction of patients, regulators and industry (Jan...
Tripartite dimension of interaction of patients, regulators and industry (Jan...Tripartite dimension of interaction of patients, regulators and industry (Jan...
Tripartite dimension of interaction of patients, regulators and industry (Jan...jangeissler
 

Mehr von jangeissler (20)

Relevanz von Laienzusammenfassungen von Studienergebnissen für Patienten
Relevanz von Laienzusammenfassungen von Studienergebnissen für Patienten Relevanz von Laienzusammenfassungen von Studienergebnissen für Patienten
Relevanz von Laienzusammenfassungen von Studienergebnissen für Patienten
 
Don't just talk about patient centricity - put meaningful patient engagement ...
Don't just talk about patient centricity - put meaningful patient engagement ...Don't just talk about patient centricity - put meaningful patient engagement ...
Don't just talk about patient centricity - put meaningful patient engagement ...
 
CML: A tiger in the cage? A (European) perspective on CML disease management
CML: A tiger in the cage? A (European) perspective on CML disease managementCML: A tiger in the cage? A (European) perspective on CML disease management
CML: A tiger in the cage? A (European) perspective on CML disease management
 
Sicht der Patienten auf Real World Data, Register und Versorgungsdaten
Sicht der Patienten auf Real World Data, Register und VersorgungsdatenSicht der Patienten auf Real World Data, Register und Versorgungsdaten
Sicht der Patienten auf Real World Data, Register und Versorgungsdaten
 
Überblick der Aktivitäten von Leukämie-Online und CML Advocates Network
Überblick der Aktivitäten von Leukämie-Online und CML Advocates NetworkÜberblick der Aktivitäten von Leukämie-Online und CML Advocates Network
Überblick der Aktivitäten von Leukämie-Online und CML Advocates Network
 
Andreas Willer - Rehabilitation für Patienten mit CML
Andreas Willer - Rehabilitation für Patienten mit CMLAndreas Willer - Rehabilitation für Patienten mit CML
Andreas Willer - Rehabilitation für Patienten mit CML
 
Umfrage zur Therapiefreien Remission (TFR) der CML-Patientengemeinschaft
Umfrage zur Therapiefreien Remission (TFR) der CML-PatientengemeinschaftUmfrage zur Therapiefreien Remission (TFR) der CML-Patientengemeinschaft
Umfrage zur Therapiefreien Remission (TFR) der CML-Patientengemeinschaft
 
Patientenperspektive im Studiendesign
Patientenperspektive im Studiendesign Patientenperspektive im Studiendesign
Patientenperspektive im Studiendesign
 
Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical world
 
Changes in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical worldChanges in patient organisations - and how this changes the medical world
Changes in patient organisations - and how this changes the medical world
 
Reasonable Legal Agreements between Patient Advocates and Pharma Companies
Reasonable Legal Agreements between Patient Advocates and Pharma CompaniesReasonable Legal Agreements between Patient Advocates and Pharma Companies
Reasonable Legal Agreements between Patient Advocates and Pharma Companies
 
Bericht LeukaNET / leukaemie-online.de und CML Advocates Network
Bericht LeukaNET / leukaemie-online.de und CML Advocates NetworkBericht LeukaNET / leukaemie-online.de und CML Advocates Network
Bericht LeukaNET / leukaemie-online.de und CML Advocates Network
 
How to get the most of the EHA congress as a CML patient advocate
How to get the most of the EHA congress as a CML patient advocateHow to get the most of the EHA congress as a CML patient advocate
How to get the most of the EHA congress as a CML patient advocate
 
European Patient Perspective on Access and Innovation with Multiplex Genomic ...
European Patient Perspective on Access and Innovation with Multiplex Genomic ...European Patient Perspective on Access and Innovation with Multiplex Genomic ...
European Patient Perspective on Access and Innovation with Multiplex Genomic ...
 
Häufige Fragen von CML-Patienten und Welt-CML-Tag 2017
Häufige Fragen von CML-Patienten und Welt-CML-Tag 2017Häufige Fragen von CML-Patienten und Welt-CML-Tag 2017
Häufige Fragen von CML-Patienten und Welt-CML-Tag 2017
 
CML: What's New at EHA? Tim Brümmendorf, EHA Capacity Building Session, EHA c...
CML: What's New at EHA? Tim Brümmendorf, EHA Capacity Building Session, EHA c...CML: What's New at EHA? Tim Brümmendorf, EHA Capacity Building Session, EHA c...
CML: What's New at EHA? Tim Brümmendorf, EHA Capacity Building Session, EHA c...
 
How to get the most of EHA as a patient advocate
How to get the most of EHA as a patient advocateHow to get the most of EHA as a patient advocate
How to get the most of EHA as a patient advocate
 
PCR-Info-Projekt (Cornelia Borowczak)
PCR-Info-Projekt (Cornelia Borowczak)PCR-Info-Projekt (Cornelia Borowczak)
PCR-Info-Projekt (Cornelia Borowczak)
 
The Networked Patient Group: How technology changes the face of patient advocacy
The Networked Patient Group: How technology changes the face of patient advocacyThe Networked Patient Group: How technology changes the face of patient advocacy
The Networked Patient Group: How technology changes the face of patient advocacy
 
Tripartite dimension of interaction of patients, regulators and industry (Jan...
Tripartite dimension of interaction of patients, regulators and industry (Jan...Tripartite dimension of interaction of patients, regulators and industry (Jan...
Tripartite dimension of interaction of patients, regulators and industry (Jan...
 

Kürzlich hochgeladen

Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 

Kürzlich hochgeladen (20)

Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 

European Cancer Patient Advocacy: Introduction to the community, key stakeholder interfaces and key initiatives (Jan Geissler)

  • 1. European cancer patient advocacy: Introduction to the community, key stakeholder interfaces and key initiatives ESO Masterclass, Lisbon/PT, 23 Feb 2018 Jan Geissler jan@patvocates.net
  • 2. European cancer patient community: What I will cover in this session  Overview on Networks and umbrellas of the patient community  Collaboration with professional societies and multi-stakeholder initiatives  Involvement of the patient community in… • European Reference Networks • public private partnerships and industry initiatives • regulatory authorities • medicines research & development • CABs, evidence-based advocacy, capacity building, EHA Please make sure you ask your questions!
  • 3. Patient advocacy operates on three levels Business Use Only 3 Patient support Inform, support, navigate Health policy Influence health policy, patient care Research Contribute in partnership with clinicians, networks and industry
  • 4. EUROPEAN CANCER PATIENT COALITION: >400 mostly national patient organisations WECAN: Workgroup of leaders of 20 European Cancer patient Advocacy Networks ALL CANCERS RARE CANCERS HEMA- TOLOGY PAEDI- ATRIC EURORDIS: >600 patient organisations in rare diseases EUROPEAN PATIENTS FORUM European Cancer Patient Networks
  • 5.  Informal workgroup and “think tank” of leaders of 20 pan-European cancer patient umbrella organisations, initiated in 2015  Share workload for meetings, coordinate our representation in committees  Form a "think tank" to develop ideas on how to cross bridges between advocacy  Share resources and concepts on joint patient-driven evidence  First activities: • Reasonable Agreements on interaction of patients advocates with industry • Fair Market Value project • Coordinated approach to education of advocates • Positioning towards Stakeholder Engagement • Coordination of contribution to research in cancer advocacy
  • 6. COMMON CANCERS: • European Men Health Forum (EMHF) • European Network of Gynaecological Cancer Advocacy Groups (ENGAGe) • EuropaColon • Europa Donna • Europa Uomo • Lung Cancer Europe (LuCE) • Melanoma Patients Network Europe (MPNE) • Pancreatic Cancer Europe Network RARE CANCERS: • European Organisation of Rare Diseases (EURORDIS) • International Brain Tumour Alliance (IBTA) • International Kidney Cancer Coalition (IKCC) • International Neuroendocrine Cancer Alliance (INCA) • Thyroid Cancer Alliance (TCA) • Sarcoma Patient Advocates European Network (SPAEN) • Chordoma Foundation • European Morbus Waldenström Network • Lymphoma Coalition Europe • Acute Leukemia Advocates Network • MDS Alliance • CML Advocates Network • CLL Advocates Network • MPN Advocates Network • Myeloma Patients Europe (MPE) • Childhood Cancer International (CCI) ALL CANCERS RARE CANCERS HEMA- TOLOGY PAEDI- ATRIC European disease-specific patient advocacy networks
  • 7. Four European Reference Networks (ERNs) in cancer launched in 2017: Hematology, Rare Cancers, Pediatrics, Genetic cancers • Initiative of EU and Member States • Networks of Centers of Excellence and local healthcare providers • Establish national healthcare pathways across all EU countries • Development and adherence to clinical guidelines • Integration of healthcare and research infrastructure In 2016, European Patient Advocacy Groups’ Representatives (ePAGs) were elected by the patient community to represent patients in the ERNs
  • 8. ALL CANCERS RARE CANCERS HEMA- TOLOGY PAEDI- ATRIC Patient Organisations Workgroup & European Affairs Committee Patient Advocacy Committee with 16 PO umbrellas & full board seat Patient Organisations Workgroup & Full Membership for patient advocates Institutional Advisory Board, Training Courses Patient Roundtable Collaboration with professional societies and multi-stakeholder initiatives
  • 9. Patient involvement in regulatory authorities (e.g. EMA)
  • 10. 11 pan-European hematology networks with 264 European member organisations in Europe (in EuroBloodNet ERN) ALL CANCERS RARE CANCERS HEMA- TOLOGY PAEDI- ATRIC Chronic Myeloid Leukemia Chronic Lymhocytic Leukemia Hemochromatosis Hemophilia Immune Thrombocytopenia Lymphoma Myelodysplastic Syndromes Myeloma Myeloproliferative Neoplasms Thalassemia Waldenström's Macroglobulinemia ePAG representation Amanda Bok (EHC) Ananda Plate (MPE) Angelo Loris Brunetta (TIF) Jan Geissler (LePAF) Pierre Aumont (EWMNetwork) Sophie Wintrich (MDS Alliance) Maria Piggin (PNH) ??? (Iron disorders)
  • 11. European Reference Network (ERN) in Rare Cancers: EURACAN ALL CANCERS RARE CANCERS HEMA- TOLOGY PAEDI- ATRIC Clinical domains Sarcoma Female genital Male genital Neuroendocrine Digestive tract Endocrine Head and Neck Skin/Eye Brain/spinal cord ePAG involved in Steering Group, Task Forces and Clinical Domains Kathy Oliver (IBTA) Isabelle Manneh-Vangramberen (ECPC) Estelle Lecointe (SPAEN) Markus Wartenberg (SPAEN) Teodora Kolarova (INCA) Jo Grey (AMEND UK) Iain Galloway (MPNE)
  • 12. Patient involvement in practice within the R&D life cycle Source: Geissler, Ryll, Uhlenhopp, Leto (2016) Therapeutic Innovation & Regulatory Science (2017), doi: 10.1177/2168479017706405 High expertise in disease area required Medium expertise in disease area required Research design and planning Research priorities Research conduct and operations Dissemination communication post-approval Protocol synopsis Fundraising for research Practical considerations Patient information Informed consent Ethics review Study reporting Health Technology Assessment Post-study communication Trial Steering Committee Information to participant Setting research priorities Protocol design Investigator meetings Data & Safety Monitoring Committee Regulatory Affairs
  • 13. Involvement in public private partnerships and industry initiatives  Innovative Medicines Initiative • EUPATI (Coordination) • Big Data: HARMONY, (BIG4) • GetReal • PARADIGM • IMI Strategic Governance Group Oncology  EFPIA Patient Think Tank  Patient involvement in Investigator Meetings, Trial Protocol Review, Data Safety Monitoring Boards
  • 14. Community Advisory Boards, e.g. CML, (Hematology) Two-way dialogue of the world-wide leaders of the CML community with clinical development, medical affairs, market access, patient relations to improve patients’ well-being and outcomes  Drug development pipeline of the companies  Improving access to drugs  Improve collaboration of companies with community  Discuss patient information developed by companies CAB
  • 15. Spectrum of further activities  Evidence-based advocacy • CML Adherence Survey, CML Therapy-Free Remission project • MPE Atlas of Access to Myeloma Treatment • Lymphoma Coalition Access Report • More of this at this ESO Masterclass!  Capacity building • This ESO Masterclass in cancer patient advocacy • SPAEN‘s SmartStart • EUPATI Perceived barriers to access across countries in relation to self declared needs & health expenditure (Source: MPE Atlas of Access of to Myeloma Treatment, 2016)
  • 16. Expert patients for patient involvement in R&D: European Patients‘ Academy  14-month expert training course for patient advocates on medicines R&D , 98 graduates from 58 disease areas  500.000 individual users of EUPATI Toolbox on eupati.eu 1. Discovery of Medicines 2. Pre-clinical Development 3. Clinical Development 4. Clinical Trials 5. Regulatory Affairs, Drug Safety, Pharmacovigilance 6. Health Technology Assessment
  • 17. EUPATI Patient Expert Training Courses 1+2: 98 graduates from 58 disease areas 1 Achondroplasia 1 Adrenoleukodystrophy 1 Allergy and airways diseases 1 Arthritis 1 Asperger´s syndrome/Fibromyalge and Chronic Fatigue Syndrome 1 Asthma 1 Attention Deficit Hyperactivity Disorder 1 Autoimmune disease 1 Brain tumours 3 Breast cancer 4 Cancer 1 Cardiovascular 1 Chronic Fatigue 1 Coeliacy 1 Cystic Fibrosis 3 Diabetes 1 Disability 1 Ehlers-Danlos Syndrome 1 Endocrine tumours 2 Endometriosis 1 Epidermolysis bullosa (EB) 1 Fibromyalgia 2 Gaucher Disease 4 General advocacy 1 Genetic Disorders 3 Haemophilia 10 Hematological Cancer 1 Hereditary haemorrhagic telangiectasia (HHT) 2 HIV 1 Incontinent patients 1 Leber’s Hereditary Optic Neuropathy 1 Lipoprotein Lipase Deficiency 1 Lung conditions 1 Lupus 1 McCune Albright syndrome 3 Melanoma 1 Mental Health 4 Multiple Sclerosis 2 Muscular atrophy 6 Muscular Dystrophy 1 Neurofybromatosis 2 Paediatric 1 Paediatric Cancer 1 Parkinson's Disease 1 Primary Immunodeficiences 1 Primary Sclerosing Cholangitis/liver and bile duct disease 1 Pulmonary Hypertension 4 Rare Diseases 1 Rare diseases/Friedrich’s Ataxia 1 Rare diseases/Paroxysmal nocturnal hemoglobinuria 1 Rare diseases/Pituitary 1 Rare diseases/Tuberous Sclerosis 1 Respiratory diseases 1 Rett Syndrome 6 Rheumatic diseases 1 Sight loss 1 Thalassaemia 1 Vasculitis Names on www.eupati.eu: